Assessment of nerve growth factor levels and clinical indicators for outcome prediction in first-episode schizophrenia

doi:10.5498/wjp.120278

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

(10)

(14)

(0)

(125)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Psychiatry. Aug 19, 2026; 16(8): 120278
Published online Aug 19, 2026. doi: 10.5498/wjp.120278

Table 2 Logistic regression models of treatment response at 8-week follow-up

	B	SE	Wald	Sig	EXP (B)	95%CI for EXP (B)
	B	SE	Wald	Sig	EXP (B)	Lower	Upper
NGF₀	0.018	0.005	14.024	< 0.001	1.018	1.008	1.027
NGF₁	0.016	0.004	14.860	< 0.001	1.016	1.008	1.024
NGF₁ - NGF₀	0.085	0.025	11.662	0.001	1.088	1.037	1.143
PANSS ≥ 20% response at 2 weeks	1.990	0.791	6.331	0.012	7.312	1.552	34.446

Variance inflation factor values were all below 2.0, indicating no serious multicollinearity. CI: Confidence interval; NGF₀: Baseline nerve growth factor; NGF₁: Nerve growth factor at 2 weeks after onset of antipsychotics treatment; PANSS: Positive and Negative Syndrome Scale.

Full Size Table

Citation: Xiao WH, Wang ML, Chen KY, Yu DD, Zhao YQ, Sun JR. Assessment of nerve growth factor levels and clinical indicators for outcome prediction in first-episode schizophrenia. World J Psychiatry 2026; 16(8): 120278
URL: https://www.wjgnet.com/2220-3206/full/v16/i8/120278.htm
DOI: https://dx.doi.org/10.5498/wjp.120278

Xiao WH, Wang ML, Chen KY, Yu DD, Zhao YQ, Sun JR. Assessment of nerve growth factor levels and clinical indicators for outcome prediction in first-episode schizophrenia. World J Psychiatry 2026; 16(8): 120278 [DOI: 10.5498/wjp.120278]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.